Novo Nordisk is now launching NovoFine Plus 32G 4mm, an ultra-thin, ultra-short universal pen needle that aims to make injections more comfortable for patients with diabetes. Canada is the first country to make NovoFine Plus available and will be followed by several other countries during 2014 and 2015. NovoFine Plus is as thin as two human hairs and 4mm long, making it the shortest needle Novo Nordisk has ever made. Its thinness and length are associated with less pain and less risk of intramuscular injection.
Studies have shown that people with type 2 diabetes are often reluctant towards initiating insulin therapy, with needle anxiety cited as a common barrier to initiation. Therefore, good design and user-friendly features that take into account patient concerns, such as ease of use and comfort, are important.
As NovoFine Plus uses SuperFlow technology, it also offers patients faster injections that need less force. It is compatible with all major pen devices9 and has been designed to reduce the risk of bending or breakage.
“We know needle anxiety can be a real barrier when people with diabetes start insulin therapy, and in some people this fear really compromises their treatment. Novo Nordisk is committed to improving diabetes care and as part of our broad portfolio within treatment, devices and needles, we’re pleased to provide this new option to people with diabetes,” said Jesper Kløve, senior vice president, Device R&D, Novo Nordisk.
Date: January 20, 2014
Source: Novo Nordisk
Filed Under: Drug Discovery
